A case of resected primary pulmonary pleomorphic carcinoma with long-term survival after multidisciplinary treatment

Abstract

Background: Generally, primary pulmonary pleomorphic carcinoma is resistant to treatment and has a poor prognosis. We report a case of resected primary pulmonary pleomorphic carcinoma with long-term survival after multidisciplinary treatment. Case presentation: A 74-year-old man with a history of emphysema, pneumoconiosis, and chronic bronchitis presented with left lung nodule and left adrenal tumor based on computed tomography. We suspected clinical T1bN0M1b, stage IVB lung cancer. Adrenalectomy of the left adrenal tumor yielded a definitive diagnosis of pleomorphic carcinoma. Chemotherapy was performed despite the spontaneous regression of lung lesions. Since lung lesions re-enlarged 11 months after adrenalectomy, the left lower lobe was partially resected followed by chemotherapy. The lung lesion was the primary lesion of the adrenal tumor. There was no recurrence 100 months after the lung resection. Conclusions: The patient experienced long-term survival after multidisciplinary treatment. Both multidisciplinary treatment and immunological mechanisms caused spontaneous regression of the primary lesion.

Clinicopathological Analysis of 17 Surgically Resected Pulmonary Pleomorphic Carcinoma Cases

“…One of them (Case 5, see Tables 1 and 2 ) obtained 96 months survival and a good prognosis, suggesting the importance of multimodal therapy. 16) Because this patient had spontaneous regression of the primary lesion after adrenalectomy, immunological mechanisms may have played a role in this case. In addition to traditional chemotherapy, therapeutic effects of new anticancer agents such as immune checkpoint inhibitors (ICIs) and molecular-targeted agents (MTAs) are expected to help in PPC.…”

Precise engineering of Gemcitabine prodrug cocktails into single polymeric nanoparticles delivery for metastatic thyroid cancer cells

“…In addition, after systematic managements, unpreferred adaptation of GEM to inactive uracil metabolite analogues can be substantially inhibited since decreased catabolic effects of cytidine are abundant in the plasma membrane (Bunyatov et al., 2019 ; Iijima et al., 2020 ; Zhao et al., 2020 ). Therefore, the GEM encapsulation prodrug has been displayed to eliminate the drug deactivations and enhance the drug loading efficiency by misusing the improved permeability and retention effects (He et al., 2019 ; Thapi et al., 2019 ; Yan et al., 2019 ).…”